BRAF and melanoma: Using a panel of melanoma cell lines (BRAF inhibitor-sensitive (A375P, SKMEL5, MEL1617) or BRAF inhibitor-resistant (MEL1617R, WM983BR, MEL624)), these investigators studied the possible relationship between autophagy and vemurafenib both in vitro and in vivo [27].